Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
SORILUX (calcipotriene foam) Foam was studied in three-vehicle controlled trials. Seven hundred and thirty one subjects with plaque psoriasis, including 473 exposed to SORILUX (calcipotriene foam) Foam were treated twice daily for 8 weeks.
Adverse events reported in greater than 1% of subjects and in a higher rate in subjects treated with SORILUX (calcipotriene foam) Foam compared to vehicle were limited to erythema.